Effect of a multifactorial intervention on mortality in type 2 diabetes.
暂无分享,去创建一个
[1] R. Holman,et al. Additive effects of glycaemia and blood pressure exposure on risk of complications in type 2 diabetes: a prospective observational study (UKPDS 75) , 2006, Diabetologia.
[2] M. Harris,et al. Diabetes and decline in heart disease mortality in US adults. , 1999, JAMA.
[3] O. Pedersen,et al. Remission to normoalbuminuria during multifactorial treatment preserves kidney function in patients with type 2 diabetes and microalbuminuria. , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[4] Stephen J. Aldington,et al. Methodology for retinal photography and assessment of diabetic retinopathy: the EURODIAB IDDM Complications Study , 1995, Diabetologia.
[5] E. Barrett-Connor,et al. Chapter 19 Heart Disease and Diabetes , 2022 .
[6] B. Carstensen. Regression models for interval censored survival data: application to HIV infection in Danish homosexual men. , 1996, Statistics in medicine.
[7] Y. Jang,et al. Standards of Medical Care in Diabetes-2010 by the American Diabetes Association: Prevention and Management of Cardiovascular Disease , 2010 .
[8] R. Holman,et al. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) , 1998, The Lancet.
[9] O. Pedersen,et al. Intensified multifactorial intervention and cardiovascular outcome in type 2 diabetes: the Steno-2 study. , 2003, Metabolism: clinical and experimental.
[10] O. Pedersen,et al. Target intervention against multiple‐risk markers to reduce cardiovascular disease in patients with type 2 diabetes , 2004, Annals of medicine.
[11] R. Holman,et al. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. , 1998 .
[12] O. Pedersen,et al. Multi-targeted and aggressive treatment of patients with type 2 diabetes at high risk: what are we waiting for? , 2005, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.
[13] B. Richelsen,et al. Type 2-diabetes og det metaboliske syndrom - diagnostik og behandling , 2000 .
[14] J. Laragh,et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial , 2004, The Lancet.
[15] V. Basevi. Standards of medical care in diabetes--2007. , 2009, Diabetes care.
[17] L. Balant,et al. The kidney in maturity onset diabetes mellitus: a clinical study of 510 patients. , 1982, Kidney international.
[18] O. Pedersen,et al. Plasma N-terminal pro-brain natriuretic peptide as a major risk marker for cardiovascular disease in patients with type 2 diabetes and microalbuminuria , 2004, Diabetologia.
[19] H. Parving,et al. Albuminuria and Poor Glycemic Control Predict Mortality in NIDDM , 1995, Diabetes.
[20] John H Fuller,et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial , 2004, The Lancet.
[21] R. Collins,et al. Heart Protection Study , 2003, The Lancet.
[22] R. Holman,et al. Erratum: The UKPDS risk engine: A model for the risk of coronary heart disease in type II diabetes (UKPDS 56) (Clinical Science (2001) 101 (671-679)) , 2002 .
[23] B. Brenner,et al. Dialysis delayed is death prevented: a clinical perspective on the RENAAL study. , 2003, Kidney international.
[24] R. Collins,et al. Blood pressure, stroke, and coronary heart disease Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context , 1990, The Lancet.
[25] David Colquhoun,et al. Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up , 2002, The Lancet.
[26] K. Juel,et al. The Danish registers of causes of death. , 1999, Danish medical bulletin.
[27] Oluf Pedersen,et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. , 2003, The New England journal of medicine.
[28] Uk-Prospective-Diabetes-Study-Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) , 1998, The Lancet.
[29] Sarah Parish,et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial , 2003, The Lancet.
[30] O. Pedersen,et al. Intensive integrated therapy of type 2 diabetes: implications for long-term prognosis. , 2004, Diabetes.
[31] P. Macfarlane,et al. Long-term follow-up of the West of Scotland Coronary Prevention Study. , 2007, The New England journal of medicine.
[32] M. Fisher. Heart Disease and Diabetes , 2009 .
[33] S. Saydah,et al. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes , 2004 .
[34] P. Gæde. Intensified multifactorial intervention in patients with type 2 diabetes and microalbuminuria: rationale and effect on late-diabetic complications , 2006 .
[35] G. Moneta,et al. Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes , 2007 .
[36] O. Pedersen,et al. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study , 1999, The Lancet.
[37] R. Holman,et al. The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). , 2001, Clinical science.
[38] P Glasziou,et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial , 2005, The Lancet.
[39] F. McAlister,et al. Evidence of suboptimal management of cardiovascular risk in patients with type 2 diabetes mellitus and symptomatic atherosclerosis , 2004, Canadian Medical Association Journal.
[40] S. Colagiuri,et al. The Diabetes Control and Complications Trial , 1983, Henry Ford Hospital medical journal.
[41] S. Yusuf. Two decades of progress in preventing vascular disease , 2002, The Lancet.